Behavioral and biochemical studies of dichloromethane fraction from the Areca catechu nut

Pharmacology Biochemistry and Behavior

Volumn 65, Issue 1, 2000, Pages 1-6

  Dar, Ahsana ^a   Khatoon, Shagufta ^a  

^a UNIVERSITY OF KARACHI   (Pakistan)

Author keywords

5 Hydroxytryptamine; Antidepressant; Areca catechu; Dichloromethane fraction; Monoamine oxidase A; Synaptosomes

Indexed keywords

ARECAIDINE; ARECOLINE; DICHLOROMETHANE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BETEL NUT; CHEMICAL COMPOSITION; CONTROLLED STUDY; DEPRESSION; DRUG ISOLATION; ENZYME INHIBITION; LOCOMOTION; MASTICATION; MOTOR PERFORMANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; REDUCTION; SWIMMING;

ANIMALS; ANTIDEPRESSIVE AGENTS; ARECA; BEHAVIOR, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; METHYLENE CHLORIDE; MICE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITORS; PLANT EXTRACTS; PLANTS, MEDICINAL; RATS; RATS, WISTAR; YOHIMBINE;

EID: 0033973323     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(99)00179-3     Document Type: Article

References (34)

1. Aquila P.S.D., Collu M., Pani L., Gessa G.L., Serra G. Antidepressant-like effect of selective dopamine D1 receptor agonists in the behavioural despair animal model of depression. Eur. J. Pharmacol. 262:1994;107-111.
2. Arjungi V.K.N. Areca nut. Drug Res. 26:1976;951-956.
3. Ashby C.R. Jr., Carr L.A., Cook C., Steptoe M.M., Franks D.D. Effect of plasma from premenstrual syndrome and control patients on human platelet and rat brain synaptosome monoamine oxidase B activity. Neuropsychobiology. 25:1992;121-125.
4. Blier P., De Montigny C., Chaput Y. Modifications of serotonergic system by antidepressant treatments. Implications for the therapeutic response in major depression J. Clin. Psychopharmacol. 7:1987;24S.
5. Borsini F., Meli A. Is the forced swimming test a suitable model for revealing antidepressant activity? Psychopharmacology (Berlin). 94:1988;147-160.
6. Bosc J.J., Jarry C., Carpy A., Panoconi E., Descas P. Synthesis and antidepressant activity of 5-(1-aryl-4-piperazino)methyl-2-amino-2-oxazolines. Eur. J. Med. Chem. 27:1992;437-442.
7. Civeira J., Cervera S., Giner J., Aleln S.R., Hellstern K., Malanowski H., Wirz R., Klar K. Moclobemide versus clomipramine in the treatment of depression a multi centre study in Spain. Acta Neurol. Scand. 82:1990;48s.
8. Cooper B.R., White H.L., Beek O., Norton R.M., Rigdon G.C., Howard J.L., Kraemer G.W., Ferris R.M. Overview of the CNS pharmacology of BW 1370U87. A chemically novel, reversible, selective MAO-A inhibitor with potential to be a new antidepressant drug Drug Dev. Res. 25:1992;181-190.
9. Da Prada M., Kettler R., Keller H.H., Burkard W.P., Muggli-Maniglio D., Haefely E.W. Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J. Pharmacol. Exp. Ther. 248:1989;400-414.
10. Dar, A.: An in vitro study of pulmonary vascular reactivity and amine oxidase activity in the horse. Ph.D. dissertation Cambridge University, 1992.
11. Dar, A.; Khatoon, S.; Rahman, G.; Atta-ur-Rahman: Antidepressant activity in the extracts of Areca catechu. Second annual symposium on Basic and applied research in health care and social development. The Aga Khan University Karachi Pakistan, 1995.
12. Dar A., Khatoon S. Antidepressant effects of ethanol extract of Areca catechu in rodents. Phytother. Res. 11:1997;174-176.
13. Dar A., Khatoon S. Antidepressant activities of Areca catechu fruit extract. Phytomedicine. 4:1997;41-45.
14. Guilbault G.C., Brignac P.J., Juneau M. New substrates for the fluorometric determination of oxidative enzymes. Anal. Chem. 40:1968;1256-1263.
15. Johnston J.P. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem. Pharmacol. 17:1968;1285-1297.
16. Hocart C.H., Fankhauser B. Betal nut residues in archaeological samples of human teeth from the Mariana islands. Experientia. 52:1996;281-285.
17. Lalithakumari H., Sirsi M. Amino acids in Areca catechu Linn (N.O. Palmae). Curr. Sci. 32:1963;548.
18. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
19. Milton J.S., Tsokos J.O. Statistical methods in the biological and health sciences, Int. student ed. 1983;McGraw-Hill, London. 281-290.
20. Murphy D.L., Sunderland T., Cohen R.M. Monoamine oxidase-inhibition antidepressant. A chemical update. Psychiatr. Clin. North Am. 7:1984;549-562.
21. Nadkarni K.M. Indian materia medica, vol. 1. 1976;Popular Prakashan, Bombay. 130-133.
22. Nickel B., Szelenyi I., Schulze G. Evaluation of physical dependence liability of 1-deprenyl (selegiline) in animals. Clin. Pharmacol. Ther. 56:1994;757-767.
23. Norton S.A. Betel. Consumption and consequences J. Am. Acad. Dermatol. 38:1998;81-88.
24. O'Neill M.F., Fernandez A.G., Palacios J.M. Antidepressant-like effects of RU 24969 and the action of antidepressants in the mouse tail suspension test. Pharmacol. Biochem. Behav. 53:1996;535-539.
25. Porsolt R.D., Anton G., Blavet N., Jalfre M. Behavioural despair in rats. A new model sensitive to antidepressant treatments Eur. J. Pharmacol. 47:1978;379-391.
26. Porsolt R.D., Bertin A., Jalfre M. Behavioral despair in mice. A primary screening test for antidepressant Arch. Int. Pharmacodyn. 229:1977;327-336.
27. Prosolt R.D., Pichon M.Le., Jalfre M. Depression. A new antidepressant model sensitive to antidepressant treatments Nature. 266:1977;730-732.
28. Quinton R.M. The increase in the toxicity of yohimbine induced by imipramine and other drugs in mice. Br. J. Pharmacol. 21:1963;51-66.
29. Steru L., Chermat R., Thierry B., Simon P. The tail suspension test. A new method for screening antidepressants in mice Psychopharmacology (Berlin). 85:1985;367-370.
30. Steru L., Chermat R., Thierry B., Mico J., Lenegre A., Steru M., Simon P., Porsolt R.D. The automated tail suspension test. Acomputerized device which differentiates psychotropic drugs Prog. Neuropsychopharmacol Biol. Psychiatry. 11:1987;659-671.
31. Trullas R., Jackson B., Skolnick P. Genetic differences in a tail suspension test for evaluating antidepressant activity. Psychopharmacology (Berlin). 99:1989;287-288.
32. Versiani M., Nardi A.E., Figueira I.L.V., Stabl M. Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase-A, compared with other antidepressants and placebo. Acta Neurol. Scand. 82:1990;24s.
33. Wu H., Chen K., Shih J.C. Site-directed mutagenesis of monoamine oxidase A and B. Role of cysteines Mol. Pharmacol. 43:1993;888-893.
34. Yu P.H., Davis B.A., Boulton A.A. Aliphatic propargylamine. Potent, selective, irreversible monoamine oxidase B inhibitors J. Med. Chem. 35:1992;3705-3713.